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The incidence of malignant pleural effusion 
(MPE) is 660 per million population, resulting in 
more than 1 million people affected globally and 
representing a growing healthcare burden.1,2 In 
the United States (US) alone, more than 125,000 
hospital admissions per year are attributable to 
MPE, with an inpatient mortality of approxi-
mately 12% and an associated cost of over US$5 
billion per year.3
Lung cancer is the most common cause of MPE, 
accounting for almost half of all cases in some 
series.4 Up to 15% of lung cancer patients will 
have an MPE at presentation, and up to 50% 
will develop an MPE during the course of the 
disease.5 Other common causes are breast 
cancer and hematological malignancies, particu-
larly lymphomas.1 There is major geographical 
variation in the incidence of malignant pleural 
mesothelioma (MPM), which will be compli-
cated by MPE in more than 90% of cases.1
MPE is most often caused by direct or hematog-
enous spread of malignant cells to the visceral 
pleura with secondary seeding to the parietal 
pleura, but can also result from direct tumor inva-
sion or hematogenous spread to the parietal 
pleura.6 Malignancy can also cause a pleural effu-
sion without direct pleural involvement. This 
condition, known as a paramalignant effusion, 
can arise from various mechanisms such as 
obstructive pneumopathy, pulmonary embolism, 
lymphatic mediastinal obstruction and superior 
vena cava syndrome.7
Dyspnea is the most common symptom in patients 
with a pleural effusion, and the primary indication 
for an intervention.8 Altered chest wall mechanics 
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and caudal displacement of the diaphragm are 
considered to be the main mechanisms involved, 
but many other poorly defined processes are likely 
to contribute.9 The degree of dyspnea is often dis-
proportionate to the size of the effusion, as under-
lying lung cancer may cause both pulmonary 
collapse and pulmonary arterial infiltration, result-
ing in minimal ventilation: perfusion mismatch-
ing. Chest pain may not be a prominent symptom, 
unless chest wall invasion or MPM is present.9
An intervention for the management of MPE will 
perforce be palliative in nature, as no procedure 
has yet been shown to prolong life in this set-
ting.8,10 There is unfortunately a dearth of high-
quality evidence on the therapeutic approach to 
MPE, and not surprisingly a high degree of vari-
ability in the management of the condition.1 As 
more therapeutic options are developed, the dis-
parities in practice increase, a trend which is par-
ticularly evident when surveys completed by 
pulmonary physicians are compared with their 
surgical counterparts.11 Pulmonary physicians 
offer talc slurry pleurodesis or indwelling pleural 
catheters (IPCs) to the majority of cases where 
intervention is required and refer less than 20% 
for video-assisted thoracoscopic surgery (VATS), 
whereas almost 70% of cardiothoracic surgeons 
opt for VATS pleurodesis as first-line therapy.12
Another major limiting factor of the existing litera-
ture on MPE is the fact that outcome measures were 
radiological endpoints and ‘successful’ pleurodesis 
was seen as surrogates for successful interventions.1 
Only recently have patient-related outcome meas-
ures, including time spent in hospital (or avoidance 
of hospitalization), palliation of symptoms and qual-
ity of life (QoL), been reported as main outcomes, as 
opposed to fluid reaccumulation.1
The primary aims of this review are to provide the 
practicing clinician with an overview of the current 
evidence base on the management of MPE, and to 
provide practical guidance on how to approach 
individual cases. Ultimately management should be 
tailored around the patient’s individualized needs 
and wishes, and to an extent to local expertise.1
Body
Prognosis
MPE generally signifies incurable disease with a 
poor prognosis.1,8 The median survival is around 
3–12 months, but can vary significantly according 
to cell type, performance status of the patient, 
staging and whether a chemosensitive malignancy 
is present.10 Assessing anticipated survival in 
patients with MPE is paramount, as it will aid in 
clinical decision making and impact on the inter-
vention offered in many cases.1 The best validated 
scoring system is the LENT score (Table 1), 
which utilizes the pleural fluid analysis, Eastern 
Cooperative Oncology Group (ECOG) perfor-
mance status score and tumor type to predict sur-
vival.13 A patient with metastatic lung cancer and 
a poor performance status will, for example, have 
a significantly worse anticipated survival than a 
patient with MPM, a good performance status 
and favorable pleural fluid parameters (median 
survival 1.5 versus 10.5 months).
General principles
Once the diagnosis of an MPE is confirmed, pal-
liative measures should be considered, with the 
aims of improving QoL (minimizing dyspnea), 
limiting pleural procedures and avoiding the need 
for repeated hospital or doctor visits.9 In general, 
only symptomatic patients should be offered 
interventions which should be tailored to their 
needs.1 Many factors influence the choice of 
definitive management offered, including the 
prognosis, performance status, size/recurrence 
rate, whether or not the underlying lung will 
expand once the fluid is drained, whether or not 
therapeutic thoracentesis provided symptomatic 
relief, the chemosensitivity of the malignancy, 
local expertise and personal preferences.8,14
The treatment options for MPE are summarized 
in Table 2. A therapeutic thoracentesis provides 
immediate relief in most cases, provided other 
causes for dyspnea (e.g. pulmonary embolism) are 
not present.9 Therapeutic thoracentesis can be 
repeated (as an outpatient), especially in patients 
with slow rate of recurrence, in patients who have 
a very short anticipated survival or a poor perfor-
mance status.8 However, a definitive intervention 
should be offered to patients with a long-antici-
pated survival, given the cumulative discomforts, 
risks and costs with repeated thoracentesis.8 A 
recent retrospective cohort study found that 
guideline consistent care using definitive proce-
dures (IPC or pleurodesis) compared with repeat 
thoracentesis was associated with fewer subse-
quent procedures and complications; however, 
pleurodesis resulted in more inpatient days.15
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Asymptomatic effusions, irrespective of size, 
generally require no specific interventions.1 
Several studies have shown that only around 
half of patients with MPE require or opt for 
definitive treatment during the course of their 
disease.16,17
Table 1. The LENT score calculation (adapted from Clive and colleagues).13
Variable Score
L LDH (IU/l) in pleural fluid  
  <1500 0
  ⩾1500 1
E ECOG score  
  0 0
  1 1
  2 2
  3–4 3
N   Neutrophil : Lymphocyte ratio 
(pleural fluid)
 
  <9 0
  ⩾9 1
T Tumor type  
  Lower risk 0
   Mesothelioma  
   Hematological malignancies  
  Moderate risk 1
   Breast cancer  
   Gynecological malignancies  
   Renal cell carcinoma  
  High risk 2
   Lung cancer  
   Other  
Risk category Total score Median (IQR) 
survival (months)
 0–1 10.5 (7.5–18.5)
Moderate 2–4 4.5 (1.5–15.5)
High 5–7 1.5 (0.5–2.5)
ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range; LDH, lactate dehydrogenase.
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Minimally invasive/nonsurgical interventions
Intercostal tube drainage with chemical pleurode-
sis. Chemical pleurodesis which is achieved by 
the instillation of a sclerosant via an intercostal 
drain (ICD) is still considered by many as the 
first-line intervention in cases without a nonex-
pandable lung (NEL), particularly in patients 
with an anticipated survival of >3 months.1,18 
The improvement in QoL and other patient-
related outcomes is comparable with other inter-
ventions, although patients spend more time in 
hospital, both initially and until death, when com-
pared with IPCs.19,20
The use of talc as a pleural sclerosant was first 
described as early as 1935.21,22 In what is still the 
largest randomized controlled trial (RCT) to date 
on pleurodesis, the radiological success rate of 
talc pleurodesis was approximately 75% after 1 
month.23 The same study found that thoracos-
copy with talc poudrage was not superior to talc 
slurry via ICD, although a post-hoc analysis sug-
gested that a subgroup of lung and breast cancers 
tended to have a higher pleurodesis rate with talc 
poudrage.23
Small size talc particles have been associated with 
the development of acute respiratory distress syn-
drome (ARDS), in all probability because of sys-
temic absorption.1 However, calibrated French 
large-particle talc is believed to have less systemic 
absorption and as such does not cause ARDS.24 
Table 2. Treatment options for malignant pleural effusions.
Strategy Modality Comments and indications






Can be effective in certain malignancies, 
including lymphoma, small cell lung and breast 
cancer
Minimally invasive ICD with chemical 
pleurodesis
Aim to obliterate pleural space
 Not an option in NEL
 IPC with/without 
pleurodesis
Aim to chronically drain the pleural cavity; can 
be combined with talc pleurodesis if lung is 
not trapped (following a short period of daily 
draining); symptom-guided drainage via IPC 
offered to cases with NEL and those with a failed 
pleurodesis
 Pleuroscopy with 
pleurodesis
Talc insufflation under direct vision during 
medical thoracoscopy
Surgical VATS with pleurodesis Chemical pleurodesis or pleural abrasion under 
direct vision; Very effective, provided pleural 
apposition can be achieved
 Thoracotomy with 
pleurectomy




Infrequently performed; sometimes considered 
for refractory cases, trapped lung and for 
chylothoraces secondary to malignancy
 Extrapleural 
pneumonectomy
Highly controversial procedure offered for the 
potentially curative management of malignant 
pleural mesothelioma
ICD, intercostal tube drainage; NEL, nonexpandable lung; IPC, indwelling pleural catheter; VATS, video-assisted 
thoracoscopic surgery.
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Numerous other agents have been used to achieve 
chemical pleurodesis, including bleomycin, tetra-
cycline, doxycycline, iodopovidone, silver nitrate 
and even mistletoe.22,25,26 Many of these sclero-
sants have been associated with major systemic 
complications, such as hyponatremia, deranged 
liver enzymes and subclinical hypothyroidism 
with iodopovidone, pulmonary toxicity with bleo-
mycin, and acute kidney injury and ARDS with 
silver nitrate.8 At least two meta-analyses found 
that nonrecurrence of the effusion was more likely 
with talc than other sclerosants (except doxycy-
cline), suggesting that there is little advantage in 
using other agents over large-particle talc.27,28
There is surprisingly little high-quality evidence 
regarding the practical aspects of pleurodesis via 
an ICD, and hence major differences in practice.1 
Current available evidence suggests that small 
bore tubes (12–14F) are as effective as large bore 
drains, with potentially fewer complications.29 
Pleurodesis should only be performed once pleu-
ral apposition is achieved, and generally only once 
<150 ml is drained over 24 h.1 The traditional 
practice of rotating the patient is no longer advo-
cated, as this may lead to dislodgement of the 
ICD.18 Guidelines based on expert opinion sug-
gest clamping for an hour.18
IPCs. Tunneled IPCs are usually inserted as an 
outpatient procedure and home drainage is per-
formed, offering an ambulatory alternative to 
ICD and pleurodesis.1,30 Although the primary 
aim is to intermittently drain the MPE in order to 
maintain adequate lung expansion and relieve 
dyspnea, spontaneous pleurodesis occurs in 
approximately 24–45% of all cases, usually within 
7 weeks.9
Catheter malfunction and tract metastases (in the 
case of MPM) are observed in 9–10% of cases 
treated with IPC.31 Pleural infection (1–5%) and 
cellulitis (2–3%) are relatively uncommon.32 Skin 
flora, including Staphylococcus aureus, accounts 
for the majority of infections, while Pseudomonas 
aeruginosa and Enterobacteriaceae responsible are 
also sometimes isolated.32 Pleural infection nor-
mally occurs at least 6–8 weeks after insertion, 
suggesting that the procedure itself is unlikely 
the source.33 The vast majority are mild and 
resolve with oral antibiotic treatment, and the 
removal of the IPC is not necessary unless the 
infection fails to respond.33 The IPC also per-
mits intrapleural tissue plasminogen activator/
DNase therapy, which is sometimes employed to 
facilitate drainage.32
Patients managed with IPC spend less time in 
hospital, both initially and during the course of 
their disease, compared with pleurodesis.19 Early 
evidence suggested that both IPC and ICD with 
pleurodesis provided comparable improvement in 
shortness of breath and QoL, although some 
studies reported at least a trend towards superior 
improvements with IPC.19,34 Current evidence 
also suggests that patients treated with IPCs are 
much less likely to require further invasive pleural 
drainage procedures.20
Cost comparisons are difficult and in all probabil-
ity influenced by the healthcare system. Evidence 
using United Kingdom costings has suggested 
that the overall mean costs per year for IPC were 
not significantly different when compared with 
ICD with pleurodesis, although IPC became a 
significantly cheaper option in those who survived 
<14 weeks.35,36
The ASAP trial, which excluded all cases with 
NEL, was plagued by a high dropout rate and 
early deaths.37 The investigators, however, con-
cluded that ‘aggressive’ daily drainage (compared 
with alternative day drainage) significantly 
increased the rate of autopleurodesis (47% versus 
24%, p = 0.003) and decreased the median time 
to autopleurodesis (54 versus 90 days) in 
patients.37 QoL and patient satisfaction were sim-
ilar between the groups.37
The AMPLE study, a large open-label, multi-
center, multinational clinical trial that included 
146 patients randomized to either an IPC (n = 
74) or talc pleurodesis (n = 72) was recently pub-
lished.20 Patients randomized to the IPC arm 
spent fewer days in hospital from treatment to 
death (10 versus 12 days, p = 0.03, translating to 
6% versus 11% of patients’ remaining life span 
respectively). No significant between-group dif-
ferences in improvements in breathlessness or 
QoL were observed.20
The combination of IPC and talc pleurodesis has 
the potential advantage of facilitating early tube 
removal, thereby decreasing the inconvenience of 
regular drainage, risks of infection and mechani-
cal failure and cost.1 This approach was initially 
investigated on a small scale in two studies, 
one where an IPC was inserted at thoracoscopy 
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following talc poudrage and another where talc 
slurry was instilled via the IPC. Both studies 
demonstrated 92% success rates at 6 months.38,39
In the very recently published IPC-Plus study all 
patients underwent drainage via an IPC regularly 
on an outpatient basis.30 Patients with no evi-
dence of NEL at day 10 were randomly assigned 
to receive either 4 g of talc slurry (n = 69) or pla-
cebo through the IPC (n = 70). At day 35, a total 
of 30 of 69 patients (43%) in the talc group had 
successful pleurodesis, compared with 16 of 70 
(23%) in the placebo group (p = 0.008).30 The 
fact that the study employed only intermittent 
IPC drainage after talc may have been the reason 
for the relatively modest pleurodesis rate com-
pared with earlier studies.20 No significant 
between-group differences in effusion size and 
complexity, number of inpatient days, mortality, 
or number of adverse events were identified. No 
significant excess of blockages of the IPC was 
noted in the talc group. QoL scores and symptom 
control were also shown to be superior in the talc 
arm of the study.30
Yet another approach to combine pleurodesis and 
IPC is the silver nitrate-coated IPC. The SEAL-
MPE study was the first in-human trial designed 
to evaluate the basic safety profile of the novel sil-
ver nitrate-coated IPC (SNCIPC) device in 
MPE.40 The device was reasonably well tolerated, 
and pleurodesis after a median of 4 days was 
achieved in eight of nine patients with expandable 
lungs.40
Finally, some centers routinely insert an IPC at 
the time of talc poudrage. It has the theoretical 
advantage of earlier discharge, and having the 
IPC as backup if pleurodesis fails.15 However, 
pleurodesis failure tends to only occur after 
months, casting doubt on the merits of inserting a 
‘prophylactic’ IPC in all cases.23
Medical thoracoscopy/pleuroscopy. Physician-
performed thoracoscopic treatment of MPE is a 
validated intervention performed in endoscopy 
units under local anesthesia and conscious 
sedation.41 Pleuroscopy-assisted talc poudrage 
can offer excellent palliation to patients with 
longer expected survival, and can be performed 
at the time of a diagnostic procedure in patients 
with a high probability of MPE based on endo-
scopic findings.1 It is more invasive and resource 
consuming when compared with ICD with 
pleurodesis or IPC, but may have superior rates 
of pleurodesis in lung and breast cancer 
patients.23 Complications such as postoperative 
pneumonia and respiratory failure are more 
common after talc poudrage during pleuros-
copy than talc slurry via ICD, although pou-
drage has been reported to be more 
comfortable.23
With current advances in the cytological assess-
ment of pleural fluid and refinement of image-
guided parietal pleural biopsies and liquid biopsies 
(e.g. circulating tumor DNA) which are increas-
ingly used in countries with high epithelial growth 
factor receptor mutations for lung cancer, rela-
tively fewer patients will likely undergo diagnostic 
pleuroscopy in the future.1,42
Surgical interventions
VATS. VATS is generally considered as more 
invasive and resource consuming than the inter-
ventions discussed above. It is performed under 
general anesthesia via multiple access ports, 
usually with single-lung ventilation which is 
achieved by means of double lumen endotra-
cheal intubation.1 Advantages include the fact 
that it permits the complete deflation of a lung, 
hence superior visualization and access for inter-
ventions, while allowing assessment of the 
underlying lung’s ability to fully expand while 
being inflated with positive pressure.1 The latter, 
if adequate, is often followed by pleurodesis. 
Other potential benefits are the ability to perform 
mechanical abrasion of the visceral and parietal 
surfaces, and even parietal pleurectomy.1,43 
Some centers even perform decortication in 
order to expand a lung that is trapped by malig-
nant infiltration of the visceral pleura, although 
this is associated with a higher complication rate 
including persistent air leak.44–46
While there is major heterogeneity in practice, 
most centers would only perform VATS in 
patients who are deemed fit for surgery. Most 
studies report a success rate of >90%, although 
this is highly dependent on the definition of suc-
cessful pleurodesis and patient selection.44,47 
VATS has the advantage of potential liberation 
from an MPE until death without the need for 
any further interventions. Although patients with 
poor lung functions are generally excluded from 
studies, VATS under sedation with local anesthe-
sia (also known as ‘tubeless’) are increasingly 
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being offered to poor surgical candidates.48 
Another relatively recent development is the use 
of thoracoscopes with a diameter of 2 mm or 
flexi-rigid pleuroscopes to perform 
‘mini-VATS’.49
Protagonists of VATS pleurodesis will highlight 
the seemingly obvious advantages: The ability to 
perform adhesiolysis and distribute talc evenly in 
the pleural space.1 There is, however, no evidence 
to support the notion that VATS pleurodesis is 
superior to bedside ICD and instillation of a scle-
rosant like talc slurry.1 The largest RCT of VATS 
in MPE to date failed to show a significant differ-
ence in the success rate of the interventions.23 
Three smaller studies also failed to demonstrate 
superiority in terms of pleurodesis success 
rate.50–52 Similarly, a meta-analysis and a more 
recent retrospective study of MPM patients also 
could not demonstrate any significant benefit of 
VATS over more conservative measures.16,53 
Moreover, the median length of hospital stay for 
an uncomplicated VATS pleurodesis is 5.8 to 
10.7 days.44 It has an inhospital mortality rate of 
1–8%.23,44,54 Up to a quarter of patients may expe-
rience some complications, both short-term (fever, 
atelectasis, pneumonia, and prolonged air leak) 
and long-term (post-VATS chest wall pain).23,44,55
Other surgical procedures. Pleuroperitoneal 
shunts that are tunneled under the skin from the 
chest to the abdomen can be inserted for patients 
with NEL.56,57 Fluid is manually pumped by 
means of a pumping chamber in the subcutane-
ous tissue overlying the costal margin. Due to the 
limited volume of the pump chamber, pumping 
may be required more than 100 times per 24 h, 
necessitating great compliance from the patient 
or carers.1 A 95% successful palliation rate was 
reported in a retrospective study, but 15% devel-
oped complications, including technical failure, 
infection and shunt-fracture.56 Concomitant asci-
tes is a contraindication for pleuroperitoneal 
shunting.
Extrapleural pneumonectomy is a highly contro-
versial procedure offered by some centers for the 
attempted cure of MPM. It carries significant 
morbidity and mortality. In fact, the MARS study 
found that the radical surgery approach signifi-
cantly shortened survival by 5.1 months.58 The 
subsequent MesoVATS study found no survival 
difference between VATS partial pleurectomy 
and talc pleurodesis (either slurry or poudrage).59 
Patients randomized to VATS partial pleurec-
tomy did however spend more time in hospital 
and experienced more procedure-related 
complications.59
Patient-centered approach
Despite the relatively small evidence base and the 
gross heterogeneity in the management of MPE, 
certain principles should be employed to guide 
the management in a particular patient. 
Interventions to manage MPE must be individu-
alized and should generally only be offered to 
patients who have experienced symptomatic 
improvement following initial therapeutic thora-
centesis or those in whom benefit is extremely 
likely (i.e. patients who are breathless with no 
other identifiable cause). Further management 
should be guided by practical aspects, for exam-
ple, the ability of the underlying lung to expand, 
the performance status of the patient, their 
expected survival and most importantly, the 
patient’s preference.
An approach which is based on current evidence 
is summarized in Figure 1. Repeated therapeutic 
thoracenteses should realistically only be offered 
to patients with a very slow rate of reaccumula-
tion and an extremely short anticipated survival 
or poor performance status. It should be avoided 
in most cases, given the cumulative risk, discom-
fort, and costs and frequency of pleural proce-
dures. Definitive management should be offered 
to these patients, but can be deferred if no reac-
cumulation is observed, as is sometimes seen in 
patients with chemosensitive malignancies.
Patients who do not have a NEL, and in whom 
apposition of the pleura can be achieved, are can-
didates for either chemical pleurodesis (via ICD) 
or an IPC (preferably with pleurodesis). Personal 
preferences, local expertise, and prognosis may 
dictate the choice in these cases, as both 
approaches have an equal impact on symptom 
relief and QoL, with the only real difference being 
less time spent in hospital with an IPC, and a 
lower rate of requiring further pleural interven-
tions (22% versus 4%).
Many would advocate that an IPC, unless con-
traindicated, should be inserted in all patients 
with symptomatic MPE, as this approach would 
reduce the need for further pleural interventions 
and reduce hospital days in the remainder of the 
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patients life.20 Daily vacuum bottle drainage for at 
least 2 weeks is encouraged, based on higher 
pleurodesis rate.37 If the lung fully expands, talc 
should be instilled via the IPC, and if pleurodesis 
is achieved, the IPC may be removed.30 Patients 
with symptomatic MPE presenting with a NEL 
and those with a failed pleurodesis are candidates 
for symptom-guided drainage via IPC.
Chemical pleurodesis at the time of diagnostic 
pleuroscopy (when overt malignant changes are 
present) is a very reasonable intervention in 
patients where lung expansion is likely. Similarly, 
VATS pleurodesis may be offered to a subgroup 
of surgically fit candidates with a long-anticipated 
survival.
Conclusion
The presence of an MPE implies advanced dis-
ease, and as such clinicians should tailor their 
expectations of the outcomes of an intervention. 
Prolongation of life will not be possible, and pal-
liation of symptoms is therefore the primary aim. 
A therapeutic thoracentesis provides immediate 
relief in most cases, provided other causes for 
dyspnea are not present. Therapeutic thoracente-
sis can be repeated, especially in patients with 
slow rate of recurrence or a very short anticipated 
survival. Definitive interventions, individualized 
according to the patient’s wishes, performance 
status, prognosis and other practical considera-
tions (including the ability of the underlying lung 
to expand) should be offered to the remainder of 
patients with MPE. Chemical pleurodesis 
(achieved via ICD or pleuroscopy) and IPC have 
equal impact on patient-based outcomes, 
although patients treated with IPC spend less 
time in hospital and fewer pleural reinterventions. 
Talc slurry via IPC is a new and potentially attrac-
tive option for patients who do not have a NEL.
Expert commentary
People afflicted by MPE are a highly diverse group 
of patients. Yet, despite vast differences in the 
underlying malignancy and its chemosensitivity, 
involvement of the underlying lung (particularly 
Figure 1. A suggested general approach to general management of MPEs.
See text for details.
IPC, indwelling pleural catheter; ICD, intercostal drain; MPE, malignant pleural effusion; NEL, nonexpandable lung; VATS, 
video-assisted thoracoscopic surgery.
*An IPC, unless contraindicated, should be inserted in the majority patients with symptomatic MPE. Daily vacuum bottle 
drainage for at least 2 weeks is encouraged. If the lung fully expands, talc should be instilled via the IPC, and if successful, 
the IPC may be removed. Patients with symptomatic MPE presenting with a NEL and those with a failed pleurodesis are 
candidates for symptom-guided drainage via IPCs.
**Can be combined with decortication if pleural apposition is not possible; generally reserved for fit surgical candidates.
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its ability to expand), major comorbidities, perfor-
mance status, anticipated survival and patient’s 
wishes, MPE is often still managed with a ‘one 
size fits all’ approach. While no intervention cur-
rently prolongs life or even directly decreases fluid 
formation, several interventions have been shown 
to impact on QoL, symptom control and the need 
for inpatient care.
One of the greatest challenges is to provide indi-
vidualized care by phenotyping patients with 
MPE.60 Clinicians have traditionally been poor at 
predicting prognosis. Even in large RCTs, where 
enrolment criteria included an expected survival 
of ⩾3 months, about a quarter of patients did not 
survive 3 months.23 The LENT score has fortu-
nately changed this landscape, allowing for more 
accurate prognostication and thus practical guid-
ance in individual cases.13 However, the estima-
tion of prognosis may once again become 
challenging in the era of personalized chemother-
apy based on cancer epigenetics.1
The ideal prediction model for successful pleu-
rodesis is still unknown, but female sex, a higher 
Karnofsky performance score, a normal fluid 
pH and a higher adenosine deaminase (ADA) 
level (>18 IU/l) have been statistically associ-
ated with successful pleurodesis, whereas a high 
pleural fluid C-reactive protein (CRP), a high 
lactate dehydrogenase (LDH) level and low 
pH have a been shown to predict failure of 
pleurodesis.61,62
Another challenge is predicting who will benefit 
from early pleurodesis or IPC placement, as 
symptomatic response after therapeutic pleural 
drainage remains variable.60 A recent multivari-
ate analysis found that patients with low pleural 
fluid pH, large effusions, and increasing age were 
more likely to require pleurodesis or IPC place-
ment for fluid control.60 The currently ongoing 
PLEASE study is the first large prospective study 
to characterize the physiological and sympto-
matic responses of fluid evacuation, which may 
represent the first step in the journey towards 
improved understanding of the mechanisms of 
dyspnea in MPE.63
A significant advance in our approach to MPE 
was shifting the goalposts from ‘radiologically 
successful’ pleurodesis to patient-centered out-
comes, particularly dyspnea. A novel breathless-
ness score for MPE, using a 100-mm visual 
analog scale, was recently validated, and subse-
quently incorporated into several prospective 
studies.64 Despite these advances, it should be 
appreciated that even these endpoints have limi-
tations. The advent of actigraphy has shown 
promise as an all-encompassing endpoint that 
incorporates control of breathlessness, pain and 
deconditioning as well as muscle wasting, mood/
depression and comorbidity. A recent study of 
actigraphy found that MPE patients have very 
poor daily activity levels, and that measurements 
of activity (such as step counts and bouts of mod-
erate/vigorous activities) correlated with conven-
tional ECOG scores.65
Despite the fact that VATS is still commonly per-
formed in the management of MPE, its true effi-
cacy compared with far less invasive procedures is 
largely unknown and its use chiefly supported by 
case series from large volume centers.12 Clearly 
an RCT in which MPE patients with good prog-
nosis are randomized to VATS or IPC (plus pleu-
rodesis if appropriate) is long overdue.
The recent finding that talc instilled via an IPC in 
patients with no evidence of NEL at 10 days post-
insertion has the potential to revolutionize the 
minimally invasive management of MPE.30 Not 
only did it lead to a clinically and statistically sig-
nificant improvement in pleurodesis rates without 
adverse events, but it also to improved QoL scores 
and symptom control. The implications of these 
findings are substantial: by facilitating early cath-
eter removal this intervention reduces the incon-
venience of regular drainage, risk of infection, 
mechanical failure and costs of the consumables.
A 5-year view
Pleural medicine, and particularly the manage-
ment of MPE, will continue to come of age and 
move from an era of expert opinion (based on 
‘collective experience’) and anecdotal reports to 
one based on high level evidence. The value and 
safety of existing and recent minimally invasive 
interventions such as chemical pleurodesis, IPC 
(with and without pleurodesis) have been rigor-
ously tested by several RCTs over the past few 
years. Moreover, the long overdue shift from 
‘successful pleurodesis’ as an endpoint in RCTs 
to patient-centered outcomes was finally made.
What still needs refinement is our ability to pro-
vide tailored care for patients with MPE, and to 
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accurately guide clinicians and patients with 
regards to the choice of ICD with pleurodesis and 
IPC with or without pleurodesis. Greater under-
standing of the mechanisms of dyspnea and thus 
the optimal intervention to address symptoms 
will be investigated, and a shift away from inva-
sive measures such as VATS is anticipated. 
Furthermore, the subgroup of relatively fit 
patients who may benefit from VATS (even with 
decortication or pleurectomy) will become better 
defined.
Novel sclerosants and drug-eluting IPCs will be 
investigated during the next 5 years, as well as the 
optimal manner of combining IPC and pleurode-
sis with regards to timing and practical considera-
tions.40 Ancillary therapy such as exercise and 
dietary interventions may also emerge as benefi-
cial adjuncts to pleural interventions in the holis-
tic approach to the patient with MPE.1
Future studies may very well include more 
patient-based outcomes. In addition to visual 
analog scales for pain and dyspnea and QoL 
questionnaires, more objective assessments of 
daily activity by means of actigraphy via a triax-
ial accelerometer could provide better insight 
into the true influence on QoL of the various 
interventions.65 Supportive therapy such as exer-
cise training, nutritional interventions and psy-
chological support have rarely been investigated, 
but could hold significant role in MPE care for 
patients.66
Ultimately, large multicenter RCTs with various 
arms, stratified according to patient characteris-
tics and comparing interventions ranging from 
surgical to minimally invasive methods of achiev-
ing pleurodesis or preventing fluid accumulation 
are needed to attain the ultimate goal of ‘person-
alized’ management.
Key issues
 • An intervention for the management of 
MPE will perforce be palliative in nature, as 
no pleural procedure has yet been shown to 
prolong life.
 • A therapeutic thoracentesis provides imme-
diate relief in most cases, provided other 
causes for dyspnea are not present.
 • Therapeutic thoracentesis can be repeated 
in patients with slow rate of fluid reaccu-
mulation and patients who have a very short 
anticipated survival or poor performance 
status.
 • Definitive interventions, individualized 
according the patient’s wishes, performance 
status, prognosis and other practical con-
siderations (including the ability of the 
underlying lung to expand) should be 
offered to the remainder of patients with 
MPE.
 • Various surgical and nonsurgical options 
are available, but insufficient evidence 
exists to guide management in most clinical 
scenarios.
 • Chemical pleurodesis (achieved via ICD or 
pleuroscopy) and IPC have equal impact 
on patient-based outcomes, although 
patients treated with IPC do spend less 
time in hospital.
 • Talc slurry via IPC is a new and potentially 
attractive option for patients who do not 
have a NEL.
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